Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs PubMatic Inc (PUBM) Price & Performance

Mesoblast LimitedTrade
PubMatic IncTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs PubMatic Inc — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while PubMatic Inc trades at $17.52 (market cap $808.97M). The key difference: Mesoblast Limited is far larger — about 2.7× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

MESOPUBM
Market Cap
$2.16B$808.97M
Sector
TechnologyTechnology
52-Week High
$20.96$17.78
52-Week Low
$12.88$6.28
Enterprise Value
$2.17B$712.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

PubMatic Inc

PUBM's stock surged 31.9% to $17.78, reflecting strong investor optimism following a Q2 2026 earnings beat with 10.5% revenue growth and improved profitability in mobile app and CTV segments. Technical indicators show a bullish trend with support at $17 and resistance at $18, though RSI levels suggest overbought conditions. The company maintains a robust balance sheet with $120M in cash and positive operating cash flow of $81.06M in 2025, despite a net loss of -$14.46M. Recent leadership changes, including the appointment of a new Global Chief Revenue Officer, aim to accelerate growth amid AI-driven advertising transformations.

The outlook for PUBM is cautiously optimistic, with a consensus price target of $21.50 offering 21% upside potential. Key opportunities include double-digit revenue growth in high-margin segments and AI product adoption, but risks persist from competitive pressures, profitability challenges, and reliance on digital advertising cyclicality. Investors should weigh the strong analyst buy ratings against elevated valuation multiples and execution risks in a dynamic market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About PubMatic Inc

PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.

Read more on PUBM